ERBB2 and breast carcinoma: Moreover, curcumin (1.5 μM) sensitized the AU565 breast cancer cells treated with quercetin (4 μM) and optiberry (2 μg/mL) to decrease lapatinib-mediated HER2 overexpression via the downregulation of HER2/Akt signalling pathways [74].